shionogi

Second Medium-Term Business Plan

Shifting from Laying the Foundation to Making Significant Strides

(April 2005–March 2010)

Considering the period of its second medium-term management plan to be a period for making significant strides over the long term, the Shionogi Group is progressively creating the global R&D and marketing systems needed to support its continuous growth in the future.

Generating In-house Products with Global Competitive Power

Shionogi has been focusing on the three targeted therapeutic areas of infectious diseases, pain, and metabolic syndrome as well as on such frontier areas as allergy treatments. In fiscal 2009, the Company expects to move five globally competitive in-house drug candidates to Phase II or further.

Generating In-house Products with Global Competitive Power

Concentrating Resources on Strategic Products

Shionogi plans to maximize its market share by continuing to concentrate resources on three products—Crestor®, Irbetan®, and Cymbalta®—as the Company's medium-to-long term growth drivers with an eye towards fiscal 2010 or further.

  • Crestor®Anti-hypercholester-olemia. Used to treat hyperlipidemia, and prevent atheroscle- rosis.
  • Irbetan®A long-acting angiot- ensin II receptor blocker (ARB) for treating hypertension with an outstanding hypotensive effect.
  • Cymbalta®NDA filing has been submitted in Japan as an antidepress- ant, and it received marketing and man- ufacturing approval in January, 2010.

Increasing Growth Tracks

Shionogi will concentrate on achieving its second medium-term management plan targets, and undertake full-scale globalization measures in order to sustain its growth over the long term.

  • Net Sales
  • Operating Income
  • Net Income
  • R&D Expenses

Aiming to simultaneously develop in-house products in the three regions of Japan, the United States, and Europe

Aiming to simultaneously develop in-house products in the three regions of Japan, the United States, and Europe
in-house products being developed globally
•
Infectious diseases: S-349572/S-265744/S-247303
•
Pain: S-297995
•
Metabolic syndrome: S-2367, S-234462
•
Frontier areas: S-555739, S-444823, S-888711, S-222611

page top